Travere Therapeutics, Inc. $TVTX Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 3.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 684,543 shares of the company’s stock after purchasing an additional 22,940 shares during the period. Charles Schwab Investment Management Inc. owned 0.77% of Travere Therapeutics worth $12,267,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of TVTX. CANADA LIFE ASSURANCE Co boosted its stake in Travere Therapeutics by 237.8% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 23,318 shares of the company’s stock valued at $406,000 after acquiring an additional 16,416 shares in the last quarter. MetLife Investment Management LLC grew its holdings in shares of Travere Therapeutics by 8.7% during the fourth quarter. MetLife Investment Management LLC now owns 44,711 shares of the company’s stock worth $779,000 after purchasing an additional 3,568 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Travere Therapeutics by 211.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 21,367 shares of the company’s stock worth $372,000 after purchasing an additional 14,501 shares during the last quarter. Syon Capital LLC purchased a new position in shares of Travere Therapeutics during the fourth quarter worth about $269,000. Finally, Aquatic Capital Management LLC purchased a new position in shares of Travere Therapeutics during the fourth quarter worth about $557,000.

Travere Therapeutics Stock Performance

NASDAQ TVTX opened at $17.92 on Friday. The company has a quick ratio of 1.98, a current ratio of 2.00 and a debt-to-equity ratio of 9.50. Travere Therapeutics, Inc. has a 52-week low of $8.50 and a 52-week high of $25.29. The business’s 50-day moving average price is $16.05 and its 200 day moving average price is $17.60. The firm has a market cap of $1.60 billion, a P/E ratio of -8.78 and a beta of 0.74.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.14. Travere Therapeutics had a negative return on equity of 717.68% and a negative net margin of 50.64%.The firm had revenue of $94.84 million for the quarter, compared to analyst estimates of $100.18 million. During the same quarter last year, the company posted ($0.65) earnings per share. The business’s revenue was up 111.5% on a year-over-year basis. On average, equities research analysts expect that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TVTX. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Travere Therapeutics in a report on Tuesday, July 1st. Wedbush raised their price objective on Travere Therapeutics from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Thursday, August 7th. Scotiabank reaffirmed an “outperform” rating on shares of Travere Therapeutics in a report on Thursday, August 7th. Wall Street Zen raised Travere Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, August 16th. Finally, Stifel Nicolaus raised their price objective on Travere Therapeutics from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, May 2nd. Thirteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Travere Therapeutics has an average rating of “Moderate Buy” and an average target price of $32.21.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.